Table 3.
Parameter | Nitti et al43 | Khullar et al44 | Van Kerrebroeck et al45 | ||||
---|---|---|---|---|---|---|---|
|
|
|
|||||
Placebo | Mirabegron 50 mg | Placebo | Mirabegron 50 mg | Placebo | Mirabegron 25 mg | Mirabegron 50 mg | |
Volume voided (mL) per micturition | |||||||
n | 480 | 472 | 433 | 424 | 415 | 410 | 426 |
Baseline (mean) | 156.7 | 161.1 | 157.5 | 156.3 | 164.0 | 165.2 | 159.3 |
Change from baseline (adjusted mean)† | 12.3 | 24.2 | 7.0 | 18.2 | 8.3 | 12.8 | 20.7 |
Difference from placebo (adjusted mean)† | – | 11.9 | – | 11.1 | – | 4.6 | 12.4 |
95% confidence interval | – | (6.3, 17.4) | – | (4.4, 17.9) | – | (−1.6, 10.8) | (6.3, 18.6) |
P-value | <0.001# | 0.001# | 0.15 | <0.001# |
Notes:
least squares mean adjusted for baseline, gender, and geographical region;
statistically significantly superior compared to placebo at the 0.05 level with multiplicity adjustment. Data from Mirabegron prescribing information.48